

Estimate change	↑
TP change	↑
Rating change	↔

Bloomberg	TELX IN
Equity Shares (m)	62
M.Cap.(INRb)/(USDb)	360.9 / 4
52-Week Range (INR)	6735 / 4601
1, 6, 12 Rel. Per (%)	16/-7/-14
12M Avg Val (INR M)	1461
Free float (%)	56.1

Financials & Valuations (INR b)

Y/E Mar	FY26E	FY27E	FY28E
Sales	37.5	41.9	47.3
EBIT Margin (%)	19.5	22.4	25.0
PAT	6.0	8.5	9.8
EPS (INR)	96.0	135.7	156.6
EPS Gr. (%)	(23.8)	41.4	15.4
BV/Sh. (INR)	491.4	552.2	633.8

Ratios

RoE (%)	20.2	26.0	26.4
RoCE (%)	14.9	17.6	19.8
Payout (%)	60.0	60.0	60.0

Valuations

P/E (x)	60.4	42.7	37.0
P/BV (x)	11.8	10.5	9.1
EV/EBITDA (x)	41.7	33.0	26.3
Div Yield (%)	1.0	1.4	1.6

Shareholding pattern (%)

As On	Sep-25	Jun-25	Sep-24
Promoter	43.9	43.9	43.9
DII	10.4	9.8	7.4
FII	12.5	12.7	13.6
Others	33.2	33.6	35.1

FII Includes depository receipts

CMP: INR5,793 **TP: INR4,700(-19%)** **Sell**

Execution improves; broader recovery yet to follow

Vertical divergence persists in 3Q

- Tata Elxsi (TELX) reported revenue of USD107m in 3QFY26, up 3.2% QoQ in CC terms, above our estimate of 1.8% CC. Growth was led by transportation business (up 7.3% QoQ CC), whereas HLS/Media & Communications declined 4.3%/1.3% QoQ CC. EBIT margin was 20.9% (up 240bp QoQ), above our estimate of 18.8%. Adj. PAT was up 15.7% QoQ and down 10.0% YoY at INR1,791m (above our est. of INR1,701m).
- For 9MFY26, revenue/EBIT/adj. PAT declined 2%/22%/22% YoY in INR terms compared to 9MFY25. We expect revenue/EBIT/adj. PAT to grow by 9.1%/10.5%/10% YoY in 4QFY26.
- While 3Q execution improved, TELX's growth remains uneven and largely reliant on Transportation-led ramp-ups, with Media and Healthcare continuing to lag amid cautious client spending. We value the stock at 30x FY28E EPS, with a TP of INR4,700. We maintain our Sell rating.

Our view: Transportation strength helps; HLS is likely to be bottomed out

- **Growth improving but still uneven across verticals:** 3Q revenue growth of 3.2% QoQ CC was ahead of estimates, largely led by Transportation, which grew 7.3% QoQ CC on the back of SDV-led OEM ramp-ups and normalization at a key strategic client.
- However, growth remains uneven, with Media & Comms and Healthcare & Life Sciences down sequentially due to furloughs and delayed deal awards. While management reiterated its aspiration for double-digit growth in Transportation and HLS in FY27, we think near-term growth continues to depend on deal-specific ramp-ups in selective verticals rather than a broad-based demand recovery.
- **Transportation strength does not fully offset softness elsewhere:** Transportation continues to be the key growth driver, supported by SDV programs, electrification initiatives, and rising traction in off-road vehicles and aerospace & defense. Media continues to be impacted by industry consolidation and cautious client spending. Healthcare appears to have bottomed out following regulatory program run-offs, with growth expected to resume in 4Q. We see early signs of stabilization, but consistency across verticals remains a key monitorable.
- **Margins benefited from utilization and cost control; wage headwinds ahead:** EBIT margin expanded by 240bp QoQ to 20.9%, ahead of expectations, driven by higher utilization, operating leverage, cost discipline, and a modest forex tailwind. Headcount reduction during the quarter further supported margins. However, a portion of this benefit is likely to reverse in 4Q due to the remaining wage hike impact (~65-70bp). While management targets a return to historical margins by FY27 exit through utilization improvement and efficiency gains, we expect margin normalization to be gradual as deal ramp-ups, hiring, and continued investments in GenAI and domain capabilities resume.

Abhishek Pathak - Research Analyst (Abhishek.Pathak@MotilalOswal.com)

Research Analyst -Keval Bhagat (Keval.Bhagat@MotilalOswal.com) **Tushar Dhonde** (Tushar.Dhonde@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilaloswal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

- Overall, we acknowledge improved execution in 3Q and visibility in Transportation. However, TELX's growth trajectory remains dependent on sustained OEM ramp-ups and normalization in Media and Healthcare. With ER&D demand still cautious and margin recovery back-ended, we remain watchful for sustained, broad-based consistency before turning more constructive.

Valuations and changes to our estimates

- While 3Q execution improved, TELX's growth remains uneven and largely reliant on Transportation-led ramp-ups, with Media and Healthcare continuing to lag amid cautious client spending. With demand recovery still selective rather than broad-based, we expect a modest ~6% CAGR in USD revenue over FY25-28.
- We keep our FY27 estimates unchanged but raise our FY26/FY28 by 3%/1%, reflecting stronger-than-expected 3Q execution and better near-term visibility in the Transportation vertical. However, margin expansion is expected to be gradual and back-ended, with EBIT margins improving to 22.4%. This translates into an EPS CAGR of ~7.5% over FY25-28.
- Valuations remain steep at ~43x 12-month forward P/E, which we view as difficult to justify given the lack of sustainable cross-vertical growth visibility. We value the stock at 30x FY28E EPS, with a TP of INR4,700. We maintain our Sell rating.

Beat on revenues and margins; Transportation vertical led growth

- USD revenue came in at USD107m, up 3.2% QoQ CC, above our estimate of 1.8% QoQ CC growth.
- Growth was led by transportation business (up 7.3% QoQ CC), whereas HLS/Media & Communications declined 4.3%/1.3% QoQ CC.
- In terms of geographies, America/Europe rose 10.7%/3.1% QoQ in USD terms, while India/RoW fell 10.5%/11.5%.
- EBIT margin was 20.9% (up 240bp QoQ), above our estimate of 18.8%.
- Adj. PAT was up 15.7% QoQ and down 10% YoY at INR1,791m (above our est. of INR1,701m). This excluded the one-time impact of INR957m due to new labor code.
- The net headcount decreased by 357 employees to 11,594 (down 2.9% QoQ) in 3QFY26. Attrition (LTM) increased by 20bp QoQ to 15.6%.

Key highlights from the management commentary

- Industry headwinds persist. Customers are making decisions, but they are cautious and carefully calibrated.
- In Automotive and Media, profitability pressures have remained intact, keeping cost takeout and profit improvement as key areas.
- Growth was driven by the Transportation business, aided by accelerated ramp-ups in SDV-led OEM deals won earlier in the year and the normalization of workstreams with a strategic OEM client that was impacted in the last quarter.
- There is scope to improve utilization, with large-scale hiring likely a quarter or two away, though calibrated hiring will continue for select clients.
- The company plans to reach ~80% utilization before initiating broader hiring, compared to ~75% currently.
- Management is confident of returning to historical margin levels by FY27 end.

Exhibit 1: Vertical-wise performance (QoQ, %)

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
Transportation	11.4	3.2	2.0	6.4	3.1	9.8	4.8	8.4	-3.3	-9.3	5.2	-2.0	5.7
Media and Communications	-0.8	2.5	0.3	-0.4	0.8	-11.7	1.1	-1.9	-0.2	-6.6	-3.7	4.5	-2.0
Healthcare and Life Sciences	-0.1	0.5	3.6	3.2	4.4	-10.8	-4.5	-10.5	0.5	2.9	-5.5	-4.1	-5.7

Source: Company, MOFSL

Exhibit 2: Region-wise performance (QoQ, %)

	3QFY23	4QFY23	1QFY24	2QFY24	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
Europe	6.3	4.9	7.0	10.2	4.0	-1.4	7.0	3.9	-7.7	-11.3	3.9	-1.7	10.7
Americas	3.5	-0.8	-1.4	1.5	-3.0	-4.6	-4.3	-7.7	-0.5	-6.3	-2.0	5.4	3.1
India	2.0	9.5	-0.2	-6.0	8.7	4.5	4.0	9.7	0.7	9.2	-11.9	-3.7	-10.5
RoW	7.9	-5.6	-7.2	-4.7	19.5	9.5	5.5	31.1	9.3	-7.5	15.0	2.3	-11.5

Source: Company, MOFSL

Quarterly Performance

Y/E March	FY25				FY26E				FY25	FY26E	Est. 3QFY26	Var. (% / bp)
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	4QE				
Revenue (USD m)	111	114	111	105	105	105	107	110	441	428	106	0.6
QoQ (%)	2.2	2.7	-2.5	-5.4	-0.3	0.4	1.8	3.2			1.2	59bp
Revenue (INR m)	9,265	9,551	9,392	9,083	8,921	9,181	9,535	9,912	37,290	37,549	9,480	0.6
YoY (%)	9.0	8.3	2.7	0.3	-3.7	-3.9	1.5	9.1	5.0	0.7	0.9	59bp
GPM (%)	27.2	27.9	26.3	22.9	20.9	21.1	23.3	22.8	26.1	22.1	21.5	181bp
SGA (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0bp
EBITDA	2,523	2,664	2,466	2,077	1,867	1,933	2,222	2,260	9,730	8,283	2,038	9.0
EBITDA Margin (%)	27.2	27.9	26.3	22.9	20.9	21.1	23.3	22.8	26.1	22.1	21.5	181bp
EBIT	2,252	2,393	2,207	1,830	1,625	1,699	1,994	2,023	8,681	7,341	1,782	11.9
EBIT Margin (%)	24.3	25.1	23.5	20.1	18.2	18.5	20.9	20.4	23.3	19.5	18.8	212bp
Other income	272	595	352	385	339	448	425	540	1,603	1,753	517	-17.7
ETR (%)	27.1	23.2	22.2	22.1	26.5	27.9	26.0	26.0	23.7	26.5	26.0	-3bp
Adj PAT	1,841	2,294	1,990	1,724	1,444	1,548	1,791	1,897	7,850	6,680	1,701	5.3
Exceptional items	0.0	0.0	0.0	0.0	0.0	0.0	702	0.0	0.0	702		
PAT	1,841	2,294	1,990	1,724	1,444	1,548	1,089	1,897	7,850	5,978	1,701	-36.0
QoQ (%)	-6.5	24.6	-13.3	-13.4	-16.3	7.2	-29.7	74.2			9.9	
YoY (%)	-2.5	14.7	-3.6	-12.4	-21.6	-32.5	-45.3	10.0	-0.9	-14.9	-14.5	
EPS (INR)	29.6	36.8	31.9	27.7	23.2	24.9	17.5	30.4	126.0	96.0	27.3	-36.0

Key Performance Indicators

Y/E March	FY25				FY26			FY25
	1Q	2Q	3Q	4Q	1Q	2Q	3Q	
Revenue (QoQ CC %)	2.4	0.2	0.0	-0.6	-3.9	1.0	3.2	
Margins (%)								
Gross Margin	27.2	27.9	26.3	22.9	20.9	21.1	23.3	26.1
EBIT Margin	24.3	25.1	23.5	20.1	18.2	18.5	20.9	23.3
Net Margin	19.9	24.0	21.2	19.0	16.2	16.9	18.8	21.1
Operating metrics								
Headcount	13,142	12,793	12,878	12,414	12,127	11,951	11,594	12,414
Attrition (%)	12.3	12.5	12.4	13.3	15.0	15.4	15.6	13.3
Key Geographies (YoY %)								
Europe	21.1	14.1	1.2	-9.0	-11.7	-16.4	0.4	6.4
USA	-10.0	-18.2	-16.2	-17.7	-15.7	-3.8	-0.3	-15.5



Highlights from the management commentary

3QFY26 performance and demand outlook

- Industry headwinds persist. Customers are making decisions, but they are cautious and carefully calibrated.
- In Automotive and Media, profitability pressures have remained intact, keeping cost takeout and profit improvement as key areas.
- Growth during the quarter was volume-led, supported by higher utilization.
- Growth was driven by the Transportation business, aided by accelerated ramp-ups in SDV-led OEM deals won earlier in the year and normalization of workstreams with a strategic OEM client that was impacted in the last quarter.
- Media & Communications and Healthcare & Life Sciences were impacted by seasonal furloughs in the last 1-2 weeks of the quarter and delays in some key deal awards.
- The company reiterated its aspiration for double-digit growth in Transportation and Healthcare & Life Sciences in FY27.
- EBIT margins expanded by 240bp QoQ to 20.9%, driven by operational excellence and improved utilization in line with business growth.
- There is scope to improve utilization, with large-scale hiring likely a quarter or two away, though calibrated hiring will continue for select clients.
- Margin included a ~35bp benefit from currency exchange, 200bp from operating leverage including utilization, and ~80-85bp from cost discipline, partially offset by ~110bp headwind from wage hikes for junior staff.
- The remaining wage hike impact is expected in 4Q, estimated at ~60-70% of the current quarter's impact (~65-70bp).
- The company plans to reach ~80% utilization before initiating broader hiring, compared to ~75% currently.
- Management is confident of returning to historical margin levels by FY27 end.
- Continued investments are being made in applying GenAI and AI across innovation and product engineering workflows, tailored to chosen verticals and domains, with scaling adoption across the organization.
- The new labour code may have a 15-20bp margin impact, which is expected to be offset by operational efficiencies.
- **Transportation:** Growth was led by accelerated ramp-ups in SDV-led OEM deals and normalization of programs with a strategic OEM client affected in the previous quarter, pulling in pent-up demand.
- Growth continues to be driven by SDV programs, with Electrification as another large opportunity, while ADAS maintains traction.
- Ramp-ups are nearing steady-state levels, with a meaningful portion already baked into the quarter, though further upside exists from new opportunities.
- A new program was won with a strategic US-based off-highway OEM for development of a complex operator information and control system.
- The company continues to build momentum in the automotive industry.
- Entry into off-road and adjacent businesses supported growth in 3Q. Steady growth is expected next quarter, with acceleration in the next fiscal year.
- Multiple large deals are driving growth in the top five and top 10 customers.
- It may take a quarter or two to return to earlier base levels for one anchor customer, though overall share of wallet has increased.

- Non-passenger vehicle business currently contributes ~7.5-8% of Transportation revenues, with potential to scale toward ~20% over the next 2-3 years, supported by strong logos and increasing industry spend.
- The company is doubling down on the Aerospace and Defense segment.
- **Media and Communication:** Several large deals have already ramped up, while bidding is underway for a couple of large deals expected to close in 4Q, indicating positive momentum.
- No challenges were reported in top accounts.
- The company continues to track technology convergence and invest ahead of demand, which can lead to mixed near-term outcomes for products and platforms.
- Investments such as Neuron, a network automation and orchestration platform, are viewed as ahead of their time but strategically positioned to reduce network management costs through automation rather than labor-intensive models.
- **Healthcare and Life Sciences:** The business bottomed out during the quarter following the runoff of certain large regulatory programs.
- Strong new customer additions were recorded, with confidence expressed in a return to growth in 4Q.
- Investments in GenAI-powered regulatory workflows are gaining traction, including a multi-million, multi-year deal with a European MedTech leader to transform regulatory processes and improve cycle time and quality.

Valuation and view

- While 3Q execution improved, TELX's growth remains uneven and largely reliant on Transportation-led ramp-ups, with Media and Healthcare continuing to lag amid cautious client spending.
- Valuations remain steep at ~43x 12-month forward P/E, which we view as difficult to justify given the lack of sustained, cross-vertical growth visibility. We value the stock at 30x FY28E EPS, with a TP of INR4,700. We maintain our Sell rating.


Exhibit 3: Summary of our revised estimates

	Revised			Earlier			Change		
	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E	FY26E	FY27E	FY28E
INR/USD	87.9	89.7	89.7	87.9	89.7	89.7	0.0%	0.0%	0.0%
USD Revenue (m)	428	467	527	427	464	523	0.2%	0.8%	0.8%
Growth (%)	-3.14	9.31	12.7	(3.3)	8.6	12.7	20bps	70bps	0bps
EBIT margin (%)	19.5	22.4	25.0	18.7	22.7	25.0	90bps	-20bps	0bps
Adj. PAT (INR b)	6,680	8,454	9,753	6,487	8,458	9,674	3.0%	0.0%	0.8%
Adj. EPS	107.2	135.7	156.6	104.1	135.8	155.3	3.0%	0.0%	0.9%

Source: MOFSL


Story in charts

Exhibit 4: Revenue grew 3.2% QoQ CC




Source: Company, MOFSL

Exhibit 5: EBIT margin was up 240bp QoQ




Source: Company, MOFSL

Exhibit 6: Transportation recovered in 3Q after steep decline




Source: Company, MOFSL

Exhibit 7: Media and comms is expected to recover in 4Q




Source: Company, MOFSL

Exhibit 8: HLS bottomed out in 3Q



Source: Company, MOFSL

Exhibit 9: T&M contract share increased by 2%



Source: Company, MOFSL

Operating metrics

Exhibit 10: Operating metrics

	3QFY24	4QFY24	1QFY25	2QFY25	3QFY25	4QFY25	1QFY26	2QFY26	3QFY26
Verticals (%)									
Transportation	46.5	51.4	52.8	55.7	55.0	53.4	55.8	54.7	56.6
Media and Communications	37.8	33.6	33.3	31.8	32.4	32.4	31.0	32.4	31.1
Healthcare and Life Sciences	15.7	14.1	13.2	11.5	11.8	13.0	12.2	11.7	10.8
Geographies (%)									
Europe	40.5	40.3	42.2	42.7	40.4	37.9	39.5	38.7	42.1
Americas	37.4	36.0	33.7	30.3	30.9	30.6	30.1	31.6	32.0
India	16.4	17.3	17.6	18.8	19.4	22.4	19.8	19.0	16.7
Row	5.7	6.3	6.5	8.3	9.3	9.1	10.5	10.7	9.3
Segments (%)									
Software Development and Services	97.0	97.2	97.0	97.1	97.5	96.3	97.3	96.9	97.2
System Integration and Support	3.0	2.8	3.0	2.9	2.5	3.7	2.7	3.1	2.8
Project Type (%)									
Fixed Price	49.7	47.1	50.9	50.5	51.9	50.7	51.9	56.3	54.4
Time and Material	50.0	52.1	49.1	49.0	48.1	49.3	48.1	43.7	45.6
Revenue Mix (%)									
Onsite	25.8	26.3	27.2	25.3	25.8	25.9	26.9	26.1	73.1
Offsite	74.2	73.7	72.8	74.7	74.2	74.1	73.1	73.9	26.9
QoQ growth (CC, %)									
Transportation	1.9	1.2	5.3	4.4	0.5	-9.7	0.0	-0.5	7.3
Media and Communications	-0.1	-4.0	0.5	-2.6	0.4	-6.3	-5.5	3.7	-1.3
Healthcare and Life Sciences	3.9	0.2	-4.3	-11.2	1.1	3.5	-6.7	-4.6	-4.3
Client Metrics (%)									
Top 5 Clients	43.8	46.2	47.2	45.1	44.8	46.2	44.7	44.2	49.4
Top 10 Clients	52.5	55.9	58.0	55.6	54.2	55.9	54.6	54.7	59.4
Employee Metrics (%)									
Total Employees	13,221	13,399	13,142	12,793	12,878	12,414	12,127	11,951	11,594
Attrition (%)	12.9	12.4	12.3	12.5	12.4	13.3	15.0	15.4	15.6

Source: Company, MOFSL

Financials and valuations

Consolidated - Income Statement

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Total Income from Operations	18,262	24,708	31,447	35,521	37,290	37,549	41,932	47,271
Change (%)	13.4	35.3	27.3	13.0	5.0	0.7	11.7	12.7
Employees Cost	13,038	17,050	21,834	25,057	27,561	29,266	31,485	34,251
Total Expenditure	13,038	17,050	21,834	25,057	27,561	29,266	31,485	34,251
% of Sales	71.4	69.0	69.4	70.5	73.9	77.9	75.1	72.5
Gross Profit	5,224	7,658	9,613	10,464	9,730	8,283	10,447	13,020
SG&A	0	0	0	0	0	0	0	0
EBITDA	5,224	7,658	9,613	10,464	9,730	8,283	10,447	13,020
% of Sales	28.6	31.0	30.6	29.5	26.1	22.1	24.9	27.5
Depreciation	444	557	814	994	1,049	942	1,048	1,182
EBIT	4,780	7,101	8,799	9,470	8,681	7,341	9,399	11,838
% of Sales	26.2	28.7	28.0	26.7	23.3	19.5	22.4	25.0
Other Income	338	351	576	1,017	1,603	1,753	2,097	1,418
PBT	5,119	7,452	9,375	10,487	10,284	9,093	11,496	13,256
Total Tax	1,437	1,958	1,823	2,564	2,435	2,413	3,041	3,503
Tax Rate (%)	28.1	26.3	19.4	24.5	23.7	26.5	26.5	26.4
Reported PAT	3,681	5,494	7,552	7,922	7,850	6,680	8,454	9,753
Change (%)	43.7	49.2	37.5	4.9	-0.9	-14.9	26.6	15.4
Margin (%)	20.2	22.2	24.0	22.3	21.1	17.8	20.2	20.6
Minority Interest	0	0	0	0	0	702	0	0
Adjusted PAT	3,681	5,494	7,552	7,922	7,850	5,978	8,454	9,753

Consolidated - Balance Sheet

(INR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Equity Share Capital	623	623	623	623	623	623	623	623
Total Reserves	12,899	15,386	20,235	24,434	27,977	29,985	33,769	38,851
Net Worth	13,522	16,009	20,858	25,057	28,600	30,608	34,392	39,474
Minority Interest	0	0	0	0	0	0	0	0
Borrowings	605	1,183	1,537	1,812	1,393	1,393	1,393	1,393
Other Long term liabilities	396	398	455	542	568	571	638	719
Capital Employed	14,522	17,590	22,849	27,410	30,560	32,573	36,423	41,587
Net Fixed Assets	1,511	2,512	3,174	3,825	3,092	3,276	3,486	3,722
Goodwill	186	203	162	134	88	88	88	88
Capital WIP	73	221	70	22	16	16	16	16
Other Assets	1,484	1,799	1,094	2,521	4,686	6,208	8,177	9,205
Curr. Assets, Loans&Adv.	13,914	16,957	23,135	25,367	27,975	28,067	30,021	34,179
Account Receivables	4,894	6,728	9,764	9,716	9,715	9,259	10,339	11,656
Cash and Bank Balance	1,004	1,511	1,339	1,332	1,353	1,881	2,500	5,031
Current Investments	7,725	8,294	11,051	12,806	14,992	14,994	15,022	15,057
Other Current Assets	291	424	981	1,513	1,915	1,934	2,160	2,435
Curr. Liability & Prov.	2,645	4,102	4,786	4,459	5,297	5,083	5,365	5,624
Account Payables	561	843	1,032	856	1,230	1,108	1,192	1,296
Other Current Liabilities	1,957	3,133	3,498	3,218	3,575	3,483	3,681	3,836
Provisions	126	126	256	385	492	492	492	492
Net Current Assets	11,269	12,855	18,349	20,908	22,678	22,985	24,656	28,555
Appl. of Funds	14,522	17,590	22,849	27,410	30,560	32,573	36,423	41,587

Financials and valuations

Ratios

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
Basic EPS (INR)	59.1	88.3	121.3	127.2	126.0	96.0	135.7	156.6
Cash EPS	66.2	97.2	134.3	143.2	142.8	111.1	152.5	175.5
BV/Share	217.1	257.1	334.9	402.3	459.2	491.4	552.2	633.8
DPS	48.0	42.5	60.6	70.0	75.0	57.6	81.4	93.9
Payout (%)	81.2	48.2	50.0	55.0	59.5	60.0	60.0	60.0
Valuation (x)								
P/E	98.0	65.6	47.8	45.5	46.0	60.4	42.7	37.0
Cash P/E	87.5	59.6	43.1	40.5	40.6	52.1	38.0	33.0
P/BV	26.7	22.5	17.3	14.4	12.6	11.8	10.5	9.1
EV/Sales	19.3	14.2	11.1	9.8	9.3	9.2	8.2	7.2
EV/EBITDA	67.5	46.0	36.4	33.3	35.5	41.7	33.0	26.3
Dividend Yield (%)	0.8	0.7	1.0	1.2	1.3	1.0	1.4	1.6
Return Ratios (%)								
RoE	30.1	37.2	41.0	34.5	29.3	20.2	26.0	26.4
RoCE	22.3	27.1	29.0	24.3	19.8	14.9	17.6	19.8

Consolidated - Cash Flow Statement

(InR m)

Y/E March	FY21	FY22	FY23	FY24	FY25	FY26E	FY27E	FY28E
OP/(Loss) before Tax	5,119	7,452	9,375	10,487	10,284	9,093	11,496	13,256
Depreciation	444	553	814	994	1,049	942	1,048	1,182
Interest & Finance Charges	59	94	162	203	190	0	0	0
Direct Taxes Paid	-1,237	-2,062	-1,848	-2,580	-2,239	-2,268	-3,095	-3,571
(Inc)/Dec in WC	122	-1,002	-3,097	-1,351	-242	222	-1,053	-1,367
Others	-132	-208	-538	-741	-921	-1,749	-2,030	-1,337
CF from Operations	4,374	4,827	4,867	7,012	8,120	6,240	6,367	8,164
(Inc)/Dec in FA	-388	-712	-637	-830	-162	-1,126	-1,258	-1,418
Free Cash Flow	3,986	4,116	4,230	6,182	7,959	5,114	5,109	6,745
(Pur)/Sale of Investments	-4,244	-656	-1,695	-2,745	-3,741	-1,668	-1,915	-961
Others	255	285	313	874	820	1,753	2,097	1,418
CF from Investments	-4,377	-1,083	-2,019	-2,701	-3,083	-1,042	-1,077	-961
Inc/(Dec) in Debt	-237	-271	-381	-498	-612	0	0	0
Interest Paid	0	-1	-4	-7	-14	0	0	0
Dividend Paid	-1,028	-2,989	-2,647	-3,774	-4,359	-4,671	-4,671	-4,671
CF from Fin. Activity	-1,265	-3,261	-3,031	-4,278	-4,986	-4,671	-4,671	-4,671
Inc/Dec of Cash	-1,268	483	-183	33	51	527	619	2,532
Forex Adjustment	-12	20	10	-39	-31	0	0	0
Opening Balance	2,284	1,007	1,511	1,338	1,331	1,352	1,879	2,498
Closing Balance	1,007	1,511	1,338	1,331	1,352	1,879	2,498	5,030

Investment in securities market is subject to market risks. Read all the related documents carefully before investing

NOTES

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall be within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412 and BSE enlistment no. 5028. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Depository participant services & distribution of various financial products. MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products and is a member of Association of Portfolio Managers in India (APMI) for distribution of PMS products. Details of associate entities of Motilal Oswal Financial Services Ltd. are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/Associate%20Details.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>. As per Regulatory requirements, Research Audit Report is uploaded on www.motilaloswal.com > MOFSL-Important Links > MOFSL Research Analyst Compliance Audit Report.

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg. No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement. The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets (Singapore) Pte. Ltd. ("MOCMSPL") (UEN 201129401Z), which is a holder of a capital markets services license and an exempt financial adviser in Singapore. This report is distributed solely to persons who (a) qualify as "institutional investors" as defined in section 4A(1)(c) of the Securities and Futures Act of Singapore ("SFA") or (b) are considered "accredited investors" as defined in section 2(1) of the Financial Advisers Regulations of Singapore read with section 4A(1)(a) of the SFA. Accordingly, if a recipient is neither an "institutional investor" nor an "accredited investor", they must immediately discontinue any use of this Report and inform MOCMSPL.

In respect of any matter arising from or in connection with the research you could contact the following representatives of MOCMSPL. In case of grievances for any of the services rendered by MOCMSPL write to grievances@motilaloswal.com.

Nainesh Rajani

Email: nainesh.rajani@motilaloswal.com

Contact: (+65) 8328 0276

Specific Disclosures

- Research Analyst and/or his/her relatives do not have a financial interest in the subject company(ies), as they do not have equity holdings in the subject company(ies). MOFSL has financial interest in the subject company(ies) at the end of the week immediately preceding the date of publication of the Research Report: Yes.
Nature of Financial interest is holding equity shares or derivatives of the subject company
- Research Analyst and/or his/her relatives do not have actual/beneficial ownership of 1% or more securities in the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report.
MOFSL has actual/beneficial ownership of 1% or more securities of the subject company(ies) at the end of the month immediately preceding the date of publication of Research Report: No
- Research Analyst and/or his/her relatives have not received compensation/other benefits from the subject company(ies) in the past 12 months.
MOFSL may have received compensation from the subject company(ies) in the past 12 months.
- Research Analyst and/or his/her relatives do not have material conflict of interest in the subject company at the time of publication of research report.
MOFSL does not have material conflict of interest in the subject company at the time of publication of research report.
- Research Analyst has not served as an officer, director or employee of subject company(ies).
- MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months.
- MOFSL has not received compensation for investment banking /merchant banking/brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company(ies) in the past 12 months.
- MOFSL may have received compensation or other benefits from the subject company(ies) or third party in connection with the research report.
- MOFSL has not engaged in market making activity for the subject company.

The associates of MOFSL may have:

- financial interest in the subject company
 - actual/beneficial ownership of 1% or more securities in the subject company at the end of the month immediately preceding the date of publication of the Research Report or date of the public appearance.
 - received compensation/other benefits from the subject company in the past 12 months
 - any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
 - acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
 - be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
 - received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.
 - Served subject company as its clients during twelve months preceding the date of distribution of the research report.
- The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report
- Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, not its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

This report is meant for the clients of Motilal Oswal only.

Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, enlistment as RA with Exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 - 71934200 / 71934263; www.motilaloswal.com. Correspondence Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad (West), Mumbai- 400 064. Tel No: 022 71881000. Details of Compliance Officer: Neeraj Agarwal, Email Id: na@motilaloswal.com, Contact No.:022-40548085.

Grievance Redressal Cell:

Contact Person	Contact No.	Email ID
Ms. Hemangi Date	022 40548000 / 022 67490600	query@motilaloswal.com
Ms. Kumud Upadhyay	022 40548082	servicehead@motilaloswal.com
Mr. Ajay Menon	022 40548083	am@motilaloswal.com
Mr. Neeraj Agarwal	022 40548085	na@motilaloswal.com
Mr. Siddhartha Khemka	022 50362452	po.research@motilaloswal.com

Registration details of group entities.: Motilal Oswal Financial Services Ltd. (MOFSL): INZ000158836 (BSE/NSE/MCX/NCDX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412, BSE enlistment no. 5028, AMFI registered Mutual Fund Distributor and SIF Distributor: ARN : 146822. IRDA Corporate Agent – CA0579, APMI: APRN00233. Motilal Oswal Financial Services Ltd. is a distributor of Mutual Funds, PMS, Fixed Deposit, Insurance, Bond, NCDs and IPO products.

Customer having any query/feedback/ clarification may write to query@motilaloswal.com. In case of grievances for any of the services rendered by Motilal Oswal Financial Services Limited (MOFSL) write to grievances@motilaloswal.com, for DP to dpgrievances@motilaloswal.com.